Share on StockTwits
 

Idenix Pharmaceuticals (NASDAQ:IDIX)’s share price reached a new 52-week high on Thursday, Analyst Ratings Network.com reports. The company traded as high as $7.48 and last traded at $6.96, with a volume of 930,274 shares traded. The stock had previously closed at $7.09.

A number of research firms have recently commented on IDIX. Analysts at UBS AG upgraded shares of Idenix Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note to investors on Monday. They now have a $11.00 price target on the stock, up previously from $4.00. Analysts at Credit Suisse upgraded shares of Idenix Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note to investors on Wednesday, October 16th. Three analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Idenix Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.92.

Idenix Pharmaceuticals has a one year low of $2.93 and a one year high of $7.45. The stock has a 50-day moving average of $5.48 and a 200-day moving average of $4.54. The company’s market cap is $944.7 million.

Idenix Pharmaceuticals (NASDAQ:IDIX) last posted its quarterly earnings results on Wednesday, October 30th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.04. Analysts expect that Idenix Pharmaceuticals will post $-0.92 EPS for the current fiscal year.

Idenix Pharmaceuticals, Inc (NASDAQ:IDIX) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.